Skip to content

Study · Non-randomized trial · n = 18 · 2026

4 results

Impact of setmelanotide on metabolic syndrome risk in patients with proopiomelanocortin or leptin receptor deficiencies.

Wabitsch M, Farooqi IS, Chung WK, van den Akker E, Kühnen P, Swain J, Garrison JC, Touchot N, Argente J, Clément K

The Journal of clinical endocrinology and metabolism19 Oct 2026

PMID42895739 (opens in a new tab)DOI10.1210/clinem/dgag345 (opens in a new tab)PepBankPUB-42895739
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In POMC or LEPR deficiency, most setmelanotide-treated patients improved in at least one metabolic parameter at week 52.

    In plain wordsIn POMC or LEPR deficiency, most patients improved in at least one metabolic measure compared with baseline during setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    Not applicableImprovement in at least one metabolic parameter
    Study

    n = 18

    Comparator
    Baseline
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · Approximately 1 yearAs given in this study (human).

    Source sentences

    Summary
    Most patients saw improvement in ≥1 metabolic parameter at week 52.
    2 context sentences
    Summary · context
    Patients from phase 3 studies of setmelanotide for POMC (NCT02896192) or LEPR (NCT03287960) deficiencies with complete metabolic parameter data were included in this analysis.
    Summary · context
    Metabolic parameters and metabolic severity Z scores based on body mass index (MetS-Z-BMI scores) were reported at baseline and following ∼1 year of setmelanotide treatment in these patients; subgroup analyses were conducted by sex, age, genotype, and response to treatment.
  2. 02HumanNon-randomized trialEfficacy outcome

    In POMC or LEPR deficiency, mean MetS-Z-BMI changed by -1.05 (SD 0.88) after approximately 1 year of setmelanotide.

    In plain wordsIn POMC or LEPR deficiency, metabolic syndrome severity decreased compared with baseline during setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    DecreaseMetS-Z-BMI change
    Study

    n = 18

    Comparator
    Baseline
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · Approximately 1 yearAs given in this study (human).

    Measurements

    MetS-Z-BMI change
    −1.05 score
    Overall, after about 1 year
    MetS-Z-BMI change SD
    0.88 score
    Overall, after about 1 year

    Source sentences

    Summary
    The overall mean (SD) change in MetS-Z-BMI score after ∼1 year of treatment was -1.05 (0.88).
    2 context sentences
    Summary · context
    Patients from phase 3 studies of setmelanotide for POMC (NCT02896192) or LEPR (NCT03287960) deficiencies with complete metabolic parameter data were included in this analysis.
    Summary · context
    Metabolic parameters and metabolic severity Z scores based on body mass index (MetS-Z-BMI scores) were reported at baseline and following ∼1 year of setmelanotide treatment in these patients; subgroup analyses were conducted by sex, age, genotype, and response to treatment.
  3. 03HumanObservational studyEfficacy outcome

    In setmelanotide-treated POMC or LEPR deficiency, weight-threshold achievers had greater MetS-Z-BMI reductions than nonachievers (P = .0187).

    In plain wordsIn setmelanotide-treated POMC or LEPR deficiency, weight-response achievers had larger metabolic syndrome score reductions than nonachievers.

    Peptide
    Setmelanotide
    Outcome
    DecreaseMetS-Z-BMI by weight response
    Study

    n: not reported in source

    Comparator
    Weight-threshold nonachievers
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · Approximately 1 yearAs given in this study (human).

    Source sentences

    Summary
    Among subgroup analyses, MetS-Z-BMI score reductions were significantly greater in achievers of weight-based thresholds compared with nonachievers (P = .0187) and in patients with deficiencies in POMC compared with LEPR (P = .0278).
    2 context sentences
    Summary · context
    Patients from phase 3 studies of setmelanotide for POMC (NCT02896192) or LEPR (NCT03287960) deficiencies with complete metabolic parameter data were included in this analysis.
    Summary · context
    Metabolic parameters and metabolic severity Z scores based on body mass index (MetS-Z-BMI scores) were reported at baseline and following ∼1 year of setmelanotide treatment in these patients; subgroup analyses were conducted by sex, age, genotype, and response to treatment.
  4. 04HumanObservational studyEfficacy outcome

    In setmelanotide-treated patients, POMC deficiency was associated with greater MetS-Z-BMI reductions than LEPR deficiency (P = .0278).

    In plain wordsIn setmelanotide-treated patients, POMC deficiency was linked to larger metabolic syndrome score reductions than LEPR deficiency.

    Peptide
    Setmelanotide
    Outcome
    DecreaseMetS-Z-BMI by genotype
    Study

    n: not reported in source

    Comparator
    LEPR deficiency
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · Approximately 1 yearAs given in this study (human).

    Source sentences

    Summary
    Among subgroup analyses, MetS-Z-BMI score reductions were significantly greater in achievers of weight-based thresholds compared with nonachievers (P = .0187) and in patients with deficiencies in POMC compared with LEPR (P = .0278).
    2 context sentences
    Summary · context
    Patients from phase 3 studies of setmelanotide for POMC (NCT02896192) or LEPR (NCT03287960) deficiencies with complete metabolic parameter data were included in this analysis.
    Summary · context
    Metabolic parameters and metabolic severity Z scores based on body mass index (MetS-Z-BMI scores) were reported at baseline and following ∼1 year of setmelanotide treatment in these patients; subgroup analyses were conducted by sex, age, genotype, and response to treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.